A Rare Nephrotic Syndrome Related to Chronic Lymphocytic Leukemia: Focal Segmental Glomerulosclerosis

Basit Öğe Kaydı
dc.authorid0000-0003-0238-2236
dc.authorid0009-0003-8254-5417
dc.authorid0000-0001-5897-6514
dc.contributor.authorKarakus, Volkan
dc.contributor.authorAtas, Unal
dc.contributor.authorUzuntas, Sahnura
dc.contributor.authorDere, Yelda
dc.contributor.authorMeteoglu, Ibrahim
dc.date.accessioned2026-01-24T12:26:52Z
dc.date.available2026-01-24T12:26:52Z
dc.date.issued2022
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractChronic lymphocytic leukemia (CLL) is a hematological disease characterized by the proliferation of monoclonal B-lymphocytes. Although autoimmune complications such as autoimmune hemolytic anemia and immune thrombocytopenia are common in CLL patients, nonhematological autoimmune complications are rather rare. The most common renal involvements are membranoproliferative glomerulonephritis and minimal change disease. Focal segmental glomerulosclerosis (FSGS) is predominantly associated with Hodgkin's lymphoma among hematological malignancies. FSGS associated with CLL is rarely reported in the literature, with a poor understanding of the common pathophysiology and a very limited experience with this co-occurrence. Although Rai Stage 1/Binet Stage B CLL, our 61-year-old case, who was diagnosed with secondary FSGS, which is a very rare complication, was treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. Following the treatment, a complete response was achieved about CLL, and the patient, whose renal findings recovered, is in remission and under follow-up for six years. Although the mechanisms between CLL and autoimmune complications are not fully elucidated, it is usually related to immune disorders like an abnormal T-cell response and polyclonal antibody production. While FSGS is very rare in lymphoma, its co-existence with CLL is reported only in a limited number of case reports. Steroids may be used in these patients; however, in cases not responding to steroids, treatment of the underlying CLL is required.
dc.identifier.doi10.7759/cureus.31545
dc.identifier.issn2168-8184
dc.identifier.issue11
dc.identifier.pmid36540526
dc.identifier.urihttps://doi.org/10.7759/cureus.31545
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4961
dc.identifier.volume14
dc.identifier.wosWOS:000914692800034
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofCureus Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectautoimmune disease and cancer
dc.subjectimmunosuppression
dc.subjectglomerulonephritis (gn)
dc.subjectfocal segmental glomerulosclerosis (fsgs)
dc.subjectchronic lymphocytic leukemia (cll)
dc.titleA Rare Nephrotic Syndrome Related to Chronic Lymphocytic Leukemia: Focal Segmental Glomerulosclerosis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu